Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DTC Guidance Is High Priority In First Amendment Review, FDA Says

Executive Summary

Direct-to-consumer ads are likely to be addressed by FDA early in the upcoming series of First Amendment guidances, Associate Deputy Chief Counsel Seth Ray said during the Food & Drug Law Institute Annual Education Conference in Washington, D.C. April 2

You may also be interested in...



FDA Warns Roche On Xeloda Promotion; Agency Is Keeping Close Eye On Drug

FDA is directing Roche to conduct a broad corrective campaign for the chemotherapy agent Xeloda (capecitabine)

FDA Warns Roche On Xeloda Promotion; Agency Is Keeping Close Eye On Drug

FDA is directing Roche to conduct a broad corrective campaign for the chemotherapy agent Xeloda (capecitabine)

FDA DTC Stance Is “Ideological,” Not Science-Based, Rep. Waxman Says

FDA's "slanted" interpretation of its DTC physician survey results shows the agency is straying from its science-based mission, Rep. Henry Waxman maintains

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel